Brief: Spago Nanomedical Q2 Sales SEK 459 Thousand
Aug 21 (Reuters) - Spago Nanomedical Q2 adjusted EPS SEK -0.03. * Q2 operating expenses SEK -10.255 million * Q2 net income SEK -8.152 million
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose